Download PDF
CC BY 4.0 · Indian J Med Paediatr Oncol
DOI: 10.1055/s-0044-1779275
Original Article

Real-World Experiences of Next-Generation Sequencing in Oncology: From an Indian Multicenter Registry and Collaborative Centers

Ashwin Oommen Philips 
1   Department of Medical Oncology, Christian Medical College, Ludhiana, Punjab, India
,
Soumya Surath Panda 
2   Department of Medical Oncology, Institute of Medical Sciences and Sum Hospital, Odhisha, India
,
Sunu Cyriac 
3   Department of Medical Oncology, Amala Institute of Medical Sciences, Kerala, India
,
Lalatendu Moharana
2   Department of Medical Oncology, Institute of Medical Sciences and Sum Hospital, Odhisha, India
,
Sindhu Kilaru 
2   Department of Medical Oncology, Institute of Medical Sciences and Sum Hospital, Odhisha, India
,
Spoorty Kolluri
2   Department of Medical Oncology, Institute of Medical Sciences and Sum Hospital, Odhisha, India
,
Krishnakumar Rathnam 
4   Department of Medical Oncology, Meenakshi Mission Medical College and Research Center, Madurai, India
,
S.V. Saju 
4   Department of Medical Oncology, Meenakshi Mission Medical College and Research Center, Madurai, India
,
Honey Susan Raju 
4   Department of Medical Oncology, Meenakshi Mission Medical College and Research Center, Madurai, India
,
Smita Kayal
5   Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
,
Dubashi Biswajit 
5   Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
,
Amit Sehrawat 
6   Department of Medical Oncology, All India Institute of Medical Sciences Rishikesh, India
,
Deepak Sundriyal
6   Department of Medical Oncology, All India Institute of Medical Sciences Rishikesh, India
,
Anil T. Jose
3   Department of Medical Oncology, Amala Institute of Medical Sciences, Kerala, India
,
Sreeja Raju
7   Department of Pathology, Amala Institute of Medical Sciences, Kerala, India
,
Preethi Paul
8   Department of Pathology, Christian Medical College, Ludhiana, Punjab, India
,
Prasanth Ganesan 
5   Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
› Author Affiliations Funding None declared.
› Further Information
   Permissions and Reprints

Abstract

Background The integration of next-generation sequencing (NGS) in guiding personalized therapy for oncology faces the challenges, primarily, of cost and drug accessibility. Limited data from Indian academic centers accentuate the need for comprehensive insights into the real-world applications of NGS in oncology.

Methods The Network of Oncology Clinical Trials in India (NOCI), accessible at www.noci-india.com, compiled data on patients who underwent NGS for solid organ cancers from January 1, 2018, to December 31, 2021. This study aimed to elucidate the testing indications, sample types analyzed, and the resultant impact on patient care.

Results Analysis of data from six centers included 278 subjects, with 24 specimens (9%) excluded due to quality test failure. Tissue constituted 59.7% of specimens, blood 38.5%, and both 1.8%. Predominantly, NGS was employed for identifying BRCA1/2 mutations (56%) and for targeted therapy in non-small-cell lung cancer (NSCLC; 28%). Only 41 (16%) patients with other cancers underwent multigene NGS panels in pursuit of targetable mutations. Among them, 13 exhibited targetable mutations, and 3 received treatment based on NGS findings.

Conclusion This study underscores that the majority of NGS applications focused on screening for BRCA1/2 mutations and identifying targetable mutations in NSCLC. However, among those undergoing NGS for advanced cancers, only a limited number received personalized therapy. The findings underscore the challenges of utilizing NGS in off-label indications within resource-constrained settings.

Keywords

hereditary cancer syndromes - next-generation sequencing - oncology - targeted therapy

Patient Consent

Waiver of consent was taken as it was a noninterventional retrospective descriptive study and patients' details were anonymized.




Publication History

Article published online:
30 January 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Green ED, Watson JD, Collins FS. Human Genome Project: twenty-five years of big biology. Nature 2015; 526 (7571) 29-31
    CrossrefPubMedGoogle Scholar
  • 2 Fischer OM, Streit S, Hart S, Ullrich A. Beyond Herceptin and Gleevec. Curr Opin Chem Biol 2003; 7 (04) 490-495 In
    CrossrefPubMedGoogle Scholar
  • 3 Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 1977; 74 (12) 5463-5467
    CrossrefPubMedGoogle Scholar
  • 4 Morganti S, Tarantino P, Ferraro E, D'Amico P, Duso BA, Curigliano G. Next Generation Sequencing (NGS): a revolutionary technology in pharmacogenomics and personalized medicine in cancer. Adv Exp Med Biol 2019; 1168: 9-30
    CrossrefPubMedGoogle Scholar
  • 5 Sabour L, Sabour M, Ghorbian S. Clinical applications of next-generation sequencing in cancer diagnosis. Pathol Oncol Res 2017; 23 (02) 225-234
    CrossrefPubMedGoogle Scholar
  • 6 Mathew A, Joseph S, Boby J. et al. Clinical benefit of comprehensive genomic profiling for advanced cancers in India. JCO Glob Oncol 2022; 8: e2100421
    CrossrefPubMedGoogle Scholar
  • 7 Ghosh J, Lopes G, Chopra S. Are we right on target? Is comprehensive genomic profiling ready for prime time in resource-constrained settings?. JCO Glob Oncol 2022; 8: e2200135
    CrossrefPubMedGoogle Scholar
  • 8 Mosele F, Remon J, Mateo J. et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol 2020; 31 (11) 1491-1505
    CrossrefPubMedGoogle Scholar
  • 9 Sunami K, Ichikawa H, Kubo T. et al. Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: a hospital-based study. Cancer Sci 2019; 110 (04) 1480-1490
    CrossrefPubMedGoogle Scholar
  • 10 Tan AC, Lai GGY, Tan GS. et al. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis. Lung Cancer 2020; 139: 207-215
    CrossrefPubMedGoogle Scholar
  • 11 Colomer R, Miranda J, Romero-Laorden N. et al. Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement. EClinicalMedicine 2023; 60: 102029
    CrossrefPubMedGoogle Scholar
  • 12 Suh KJ, Kim SH, Kim YJ. et al. Clinical application of next-generation sequencing in patients with breast cancer: real-world data. J Breast Cancer 2022; 25 (05) 366-378
    CrossrefPubMedGoogle Scholar
  • 13 Massard C, Michiels S, Ferté C. et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov 2017; 7 (06) 586-595
    CrossrefPubMedGoogle Scholar
  • 14 Le Tourneau C, Delord JP, Gonçalves A. et al; SHIVA investigators. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 2015; 16 (13) 1324-1334
    CrossrefPubMedGoogle Scholar
  • 15 De Falco V, Poliero L, Vitello PP. et al. Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania “Luigi Vanvitelli.”. ESMO Open 2020; 5 (02) e000675
    CrossrefPubMedGoogle Scholar